News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Dendrite International, Inc. (DRTE) Awarded Sales And Marketing Data Outsourcing Contract From Sankyo Pharma Inc.

10/19/2005 5:10:52 PM

Marks Launch of New Axon Pharma(TM) Business Intelligence Solution and Further Expansion of Dendrite's Pharmaceutical Data Management Business

MORRISTOWN, N.J.--(BUSINESS WIRE)--April 12, 2004-- Dendrite International, Inc. (NASDAQ: DRTE - News) today announced that Sankyo Pharma Inc.--the U.S. subsidiary of Tokyo-based Sankyo Co., Ltd., and one of the largest pharmaceutical companies in Japan-- has signed a four-year sales and marketing data outsourcing contract with the company. The agreement includes Dendrite's new Axon Pharma(TM) solution, which provides pharmaceutical companies business intelligence through analysis of disparate data sources.

Sankyo Pharma Signs Sales and Marketing Data Outsourcing Agreement with Dendrite

Under a new agreement with Sankyo Pharma, Dendrite will provide all aspects of data management, including server hosting, implementation, project management, and production control as well as its industry-leading customer information management and business intelligence solutions to this growing pharmaceutical company. The contract extends and expands Dendrite's strategic partnership with Sankyo Pharma, which has utilized Dendrite's sales effectiveness applications for more than seven years.

"The ability to quickly and easily collect, consolidate, manage, and share critical customer information across our enterprise enhances all aspects of promotional initiatives--from sales force alignments and targeting, to reporting and analytics," said Bill Ippolito, Chief Information Officer of Sankyo Pharma. "The depth and breadth of Dendrite's data-management capabilities, along with its industry-specific applications and expertise, distinguished it as the most credible provider of data-outsourcing services to help us achieve our corporate objectives."

Sankyo will utilize Dendrite's NUCLEUS Pharma(TM) customer management solution, which creates a centralized repository of customer information based on data cleansed from internal and external sources. Using this solution, Sankyo will be able to gain a consistent understanding of customers that can be shared across the entire enterprise to support critical decision-making.

Axon Pharma Business Intelligence Solution Launched

As part of this new agreement, Sankyo will also utilize Dendrite's newly launched Axon Pharma sales and marketing data visualization and business intelligence solution. Providing robust customer insights, it enables strategic planning and enhances tactical decision-making by providing reporting, ad-hoc querying, information mining, and analytical functions using industry-leading third party tools. Incorporating customer, prescription, sales force alignment, company product, and activity data into a centralized data mart, Axon Pharma can be used as a stand-alone solution or seamlessly integrated with Dendrite's suite of offerings to maximize deployment flexibility.

"Axon Pharma allows users to apply advanced database analytics to a single view of enterprise-wide data, yielding actionable reports for use in the home office or the field," said Dan Ballard, Vice President of Dendrite's data and analytics business. "Those who rely on accurately linked customer and peripheral data to derive business intelligence can shift their attention from legacy data integrity issues and instead focus on strengthening their business through cleansed, organized data."

Axon Pharma is the latest solution in Dendrite's expanding pharmaceutical data management business, which now encompasses database design, data standardization, matching, augmentation, and delivery. The business uniquely combines Dendrite's Validator(TM) data-cleansing services, NUCLEUS Pharma(TM) customer database management solution, and Xtelligent(TM) suite of XML-based adaptors for data exchange with the company's expertise in hosting and managing data in a production environment.

About Sankyo Pharma Inc.

Sankyo Pharma Inc. is dedicated to developing and marketing important pharmaceutical products for the U.S. market. A national sales force of 550 representatives, supported by dedicated managed care personnel, promotes Sankyo Pharma products. For more information, visit

About Dendrite

Dendrite develops and delivers solutions that increase the productivity of sales, marketing, and clinical processes for pharmaceutical and other life science clients. For more information, visit

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. All "outlook" information constitutes forward-looking statements. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve certain significant risks and uncertainties, including those which may result from our dependence on the pharmaceutical industry; dependence on major customers; economic pressures and legislative and regulatory impact on our customers; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products; our fixed expenses in relation to fluctuating revenues; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; acquisitions; our ability to attract and retain key personnel; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; results from strategic relationships; risks associated with events that may affect the world economy, including terrorism, military action in the Middle East or threat of other hostilities in the Middle East, Asia and other geographical regions; catastrophic events which could negatively affect our information technology infrastructure; difficulties disposing of certain of our facilities; and unexpected changes in accounting regulations, standards or interpretations. Other important factors that should be considered are included in the Company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.


Dendrite International, Inc. Erik Kopp, 908-541-5850

Source: Dendrite International, Inc.

Read at

comments powered by Disqus